Virtus Fund Advisers’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Virtus Fund Advisers’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.01M	Buy	+72,547	New	+$981K	0.01%	283
2014 Q3	–	Sell	-4,099	Closed	-$50K	–	2210
2014 Q2	$50K	Buy	+4,099	New	+$48.4K	﹤0.01%	1868

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtus Fund Advisers's MNTA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2017: 72,547 shares worth $1.01M. The stake represents 0.01% of the portfolio and ranks #283 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in MNTA as recently as Q2 2014.

Virtus Fund Advisers first reported a position in MNTA in Q2 2014 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold MNTA as of Q4 2017.

Virtus Fund Advisers held 72,547 shares of Momenta Pharmaceuticals, Inc. worth $1.01M as of Q4 2017.
Momenta Pharmaceuticals, Inc. was a new Virtus Fund Advisers position in Q4 2017.
Momenta Pharmaceuticals, Inc. made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #283 holding.
Virtus Fund Advisers first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
166 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.